Lung Cancer Online
Home Care Support Info Treatment Effects Tests Surviving Sites MedLit

 home > treatment > agents & regimens > Sunitinib (Sutent)

Sunitinib (Sutent) : Pfizer : Oral, multitargeted tyrosine kinase inhibitor

Efficacy and Safety of Sunitinib in Previously Treated, Advanced NSCLC (ASCO)
ASCO 2006 abstract of a phase II study that concluded sunitinib has provocative single-agent activity in previously treated patients with recurrent and advanced NSCLC, with the level of activity similar to currently approved agents. [5/06]

Sutent (sunitinib malate) (Pfizer)
Manufacturer's website with link to full prescribing information.

Sunitinib (Sutent) - Recent MEDLINE Abstracts (PubMed)

Sunitinib (Sutent)- Clinical Trials (


Feedback / Queries Disclaimer Advocacy - You Can Help

Copyright © 1999-2006, Lung Cancer Online Foundation
Last modified: 18-Feb-2009
Karen Parles, MLS Editor